期刊文献+

前列腺癌组织FHIT和PSA表达的初步研究 被引量:5

Expression of fragile histidine triad and prostate specific antigen in prostatic carcinoma
在线阅读 下载PDF
导出
摘要 目的:探讨脆性组氨酸三联体(fragile histidine triad,FHIT)与前列腺特异性抗原(prostate specific antigen,PSA)在前列腺癌组织中的表达及意义。方法:选取不同分级的前列腺癌组织(64例)和前列腺增生组织(32例),采用免疫组织化学SP法染色,检测FHIT及PSA的表达情况。结果:64例前列腺癌组织中病理分级(按Gleason分级系统)分化良好癌、中等分化癌和分化不良癌组织中FHIT的蛋白表达率分别为84.2%(16/19)、45.4%(10/22)和17.4%(4/23)。随着Gleason评分增加,FHIT蛋白表达率显著下降,P<0.05。病理分级中分化良好癌、中等分化癌和分化不良癌PSA的蛋白表达率分别为100%(19/19)、68.2%(15/22)和34.8%(8/23),随着Gleason评分增加,PSA蛋白表达率显著下降,P<0.05。结论:FHIT的表达与前列腺癌的Gleason评分负相关;PSA的表达与Gleason评分负相关;FHIT和PSA的表达呈正相关。 OBJECTIVE:To investigate the expression and significance of FHIT(fragile histidine triad) and PSA( prostate specific antigen) in prostatic carcinoma. METHODS: Prostatic carcinoma tissues of different pathological grades (64 cases) and prostatic hyperplasia tissues (32 cases) were selected. SP methord was used to detect the expression of FHIT and PSA. RESULTS: The expressing rates of FHIT in well differentiated, moderately differentiated and poorly differentiated tissues according to cell differentiating deg...
出处 《中华肿瘤防治杂志》 CAS 2008年第9期687-689,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 前列腺肿瘤/病理学 组氨酸 前列腺特异抗原/分析 免疫组织化学 prostatic neoplasms/pathology histidine prostate-specific antigen/analysis immunohistochemistry
  • 相关文献

参考文献4

二级参考文献21

  • 1顾方六.Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China[J].Chinese Medical Journal,2000(4):11-14. 被引量:17
  • 2邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 3Humphrey P. Prostate pathology. Chicago: ASCP Press, 2003. 338-375.
  • 4Eble JN, Sauter G, Sesterhen IA. Pathology and genetics of the urinary system and male genital organs. Lyon: IARC Press, 2004. 159-215.
  • 5Epstein JI. The prostate and seminal vesicles. In: Mills SE, ed. Sternberg's diagnostic surgical pathology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2004. 2083-2132.
  • 6Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol, 2004, 17:292-305.
  • 7Srigley JR, Amin MB, Bostwick DG, et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. Arch Pathol Lab Med, 2000,124:1034-1039.
  • 8Kronz JD, Silberman MA, Allsbrook WC Jr, et al. Pathology residents' use of a Web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. Hum Pathol, 2000, 31:1044-1050.
  • 9Kronz JD, Silberman MA, Allsbrook WC Jr, et al. A web-based tutorial improves practicing pathologists' Gleason grading of images of prostate carcinoma specimens obtained by needle biopsy: validation of a new medical education paradigm. Cancer, 2000, 89:1818-1823.
  • 10Gleason DF. Histologic grading and clinical staging of prostate carcinoma. In : Tannenbaum M, ed. Urologic pathology: the prostate. Philadelphia: Lea & Fibiger, 1977.171-198.

共引文献207

同被引文献57

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部